January 4, 2019
ADC Therapeutics doses first patient with metastatic solid tumor in clinical test of ADCT-301
ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.